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Summary
To study the specific actions of relaxin through RXFP1 in human cells, it would be advanta-
geous to develop cell populations with permanent RXFP1 knockdown (KD). We have devel-
oped and assessed four microRNA against human RXFP1. One of the four designed microRNA 
displayed significant RXFP1 KD as assessed by reduced relaxin binding when co-transfected 
with human RXFP1 into HEK-293T cells. The selected microRNA sequence was subsequently 
retrovirally delivered into the human dermal fibroblast cell line BJ3 which natively expresses 
RXFP1. The RXFP1 KD BJ3 cells displayed diminished RXFP1 mRNA expression and complete 
loss of ability of relaxin treatment to reduce collagen deposition after TGF-β1 stimulation. The 
retroviral expression of miRNA to successfully silence RXFP1 expression is an invaluable tool 
to investigate receptor specificity, signalling and possible off-target effects of newly developed 
relaxin analogs.
Introduction
The peptide hormone relaxin mediates its actions through the G-protein coupled 
receptor relaxin family peptide receptor 1 (RXFP1) (1). To further elucidate the specif-
ic actions of relaxin and relaxin analogues, we developed microRNA (miRNA) against 
human RXFP1 and following validation of miRNA targeting utilized retroviruses for cell 
delivery and RXFP1 KD. Recombinant retroviruses are incapable of self-replication and 
are designed to integrate a gene of interest or miRNA into the cell’s genome with stable 
expression and marked efficiency in different cell types (2, 3). The relative co-expression 
of green fluorescence protein (GFP) to miRNA in these viruses was used as marker to 
sort highly transduced cells using fluorescence activated cell sorting (FACS). To validate 
this approach, we used human BJ3 cells, a native RXFP1 expressing fibroblast cell line fre-
quently used in the study of RXFP1 mediated collagen remodelling (4).
Methods
Four miRNA were designed against human RXFP1 (accession number 
NM_021634.2) using Invitrogen BLOCK-iTTM Pol II miR RNAi Designer and Expres-
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sion Vector system and cloned into the pcDNA3.1(+) mammalian expression vector. 
The miRNA were tested by co-transfection with human RXFP1 in HEK-293T cells and 
subsequent analysis of Eu-labelled relaxin binding as previously described (5). Data 
shown are from 3 independent experiments performed in triplicate and are expressed 
as specific relaxin binding normalised to the specific binding of a RXFP1 only trans-
fection and were analysed using one-way ANOVA with Bonferroni’s multiple com-
parison post-hoc analysis. 
The selected miRNA was cloned into Murine Stem Cell Virus (MSCV) vector 
and transfected into HEK-293T cells to produce recombinant retrovirus carrying the 
miRNA transgene. The media containing the recombinant virus was used to trans-
duce BJ3 cells. After transduction, FACS was used to sort high GFP expressing cells, 
a marker for the levels of miRNA expression, to generate the RXFP1 KD BJ3 cells. 
The KD of RXFP1 in these cells was assessed using reverse-transcription PCR and 
collagen remodelling after relaxin treatment. The collagen deposition of wild-type 
and RXFP1 KD BJ3 cells treated with 4ng/ml TGF-β1 and 100ng/ml relaxin for 3 days 
was measured using hydroxyproline assays as performed previously (6). Data shown 
are from 4 independent experiments performed in duplicate. The collagen content 
of each treatment was normalised to untreated control cells and analysed using Stu-
dent’s t-test.
Results and Discussion
This study set out to develop a viral-based approach to deliver miRNA against 
RXFP1 to enable KD of RXFP1 in human cells. As there are no high affinity RXFP1 
antagonists currently available, this approach will serve as a good tool to study the 
RXFP1 specific and RXFP1 independent actions of relaxin and relaxin analogues.
Four miRNA targeting the human RXFP1 sequence were designed, cloned and 
their effectiveness assessed using relaxin binding in HEK-293T cells co-transfected 
with RXFP1 and each miRNA. One of the four (miRNA 2) was found to significantly 
KD RXFP1 expression as demonstrated by 60% reduction of specific relaxin binding 
(p<0.001) (Figure 1A). miRNA 2 was selected to develop a recombinant retrovirus to 
enable RXFP1 KD in human cells. 
BJ3 fibroblasts cells were chosen for the retroviral transduction as this line has 
similar collagen remodelling characteristics to primary fibroblasts with a greater pas-
sage capacity. As transduction efficiency varies in different cells, FACS was employed 
to select the RXFP1 KD BJ3 cells using GFP as a marker for miRNA expression. 
Assessment of the RXFP1 KD BJ3 cells showed diminished RXFP1 mRNA expres-
sion (data not shown). In addition, no reduction in TGF-β1-stimulated collagen lev-
els were observed in RXFP1 KD BJ3 cells in the presence of high concentrations of 
relaxin (100ng/ml) (Figure 1B). The complete loss of relaxin stimulated reduction in 
TGF-β1-stimulated collagen production in RXFP1 KD BJ3 cells highlights the function-
al effects of substantial KD of RXFP1 by miRNA 2 transduction (Figure 1B).
This study successfully established a retroviral delivery vector to KD RXFP1 
expression in human cells, which can be applied to any cell type. This will allow the 
identification of RXFP1 independent effects and improve the selection and develop-
ment of future drugs with greater receptor selectivity and potency.
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Figure 1. Specific relaxin binding of HEK-293T cells co-transfected with miRNA (A) and collagen content of 
wild-type and RXFP1 knockdown (KD) BJ3 cells under different treatments (B). (A) Specific binding was deter-
mined by the difference in europium labelled relaxin binding with and without unlabelled relaxin. Only miR-
NA 2 displayed a significant reduction in specific relaxin binding (p<0.001). (B). TGF-β1 stimulation resulted 
in a marked increase in collagen levels in both RXFP1 KD and wild-type BJ3 cells. Relaxin treatment reversed 
this collagen increase in wild-type cells but not in the RXFP1 KD cells, highlighting the effective RXFP1 
knockdown in these cells. Importantly relaxin treatment, or RXFP1 KD, did not influence basal collagen levels 
in these cells. *p<0.05, **p<0.01and ***p<0.001.
